Spark Therapeutics Inc (NASDAQ:ONCE) – Analysts at SunTrust Banks issued their FY2022 EPS estimates for Spark Therapeutics in a research report issued to clients and investors on Wednesday, according to Zacks Investment Research. SunTrust Banks analyst E. Nash forecasts that the biotechnology company will post earnings per share of $7.91 for the year. SunTrust Banks has a “Buy” rating and a $113.00 price objective on the stock.
Several other equities analysts have also recently commented on the stock. Raymond James Financial set a $66.00 target price on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald set a $105.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. BMO Capital Markets set a $67.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Goldman Sachs Group cut shares of Spark Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $106.00 to $58.00 in a research report on Thursday, December 14th. They noted that the move was a valuation call. Finally, Barclays restated a “buy” rating and issued a $54.00 price target on shares of Spark Therapeutics in a research report on Wednesday, December 13th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company. Spark Therapeutics currently has an average rating of “Buy” and an average target price of $76.03.
Spark Therapeutics (NASDAQ ONCE) traded down $1.41 during midday trading on Friday, reaching $52.66. 712,141 shares of the company’s stock were exchanged, compared to its average volume of 1,560,000. The company has a market cap of $1,950.00 and a P/E ratio of -7.31. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business’s quarterly revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.07) EPS.
A number of hedge funds and other institutional investors have recently bought and sold shares of ONCE. Ameritas Investment Partners Inc. increased its holdings in Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Spark Therapeutics during the second quarter worth about $143,000. BNP Paribas Arbitrage SA increased its holdings in Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the last quarter. Pacad Investment Ltd. boosted its position in Spark Therapeutics by 75.0% during the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 1,500 shares during the period. Finally, Teacher Retirement System of Texas bought a new position in Spark Therapeutics during the third quarter worth about $225,000. Institutional investors and hedge funds own 94.91% of the company’s stock.
In other news, insider Daniel Faga sold 6,000 shares of the stock in a transaction dated Friday, October 20th. The shares were sold at an average price of $79.95, for a total value of $479,700.00. Following the completion of the sale, the insider now owns 6,000 shares in the company, valued at $479,700. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the completion of the sale, the chief executive officer now owns 250,000 shares of the company’s stock, valued at approximately $17,885,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,309 shares of company stock worth $4,621,085. Corporate insiders own 7.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Brokers Offer Predictions for Spark Therapeutics Inc’s FY2022 Earnings (NASDAQ:ONCE)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/suntrust-banks-comments-on-spark-therapeutics-incs-fy2022-earnings-once.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.